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Summary The assessment of the diagnostic power of four serum tumour markers, CEA, CA 19-9, CA 50 and
CA 195 for colorectal carcinoma is described, according to recently formulated guidelines. Preoperative serum
concentrations of the four markers were determined in 198 colorectal cancer patients and 57 patients with a
benign colorectal disorder. The cumulative frequency distributions of the malignant and benign group show
strong overlap for all markers, which indicates low diagnostic ability. This is confirmed by the Receiver
Operating Characteristic curves, which have areas under the curve of 0.65 (95% confidence interval (CI)
0.58-0.73) for CA 19-9, CA 50 and CA 195 and of 0.70 (95%) CI 0.63-0.77) for CEA. The new tumour
markers appear to be of slightly less diagnostic value than CEA for the primary diagnosis ofcolorectal cancer,
although the discrepancy is not statistically significant. The low diagnostic power of CA 19-9, CA 50 and CA
195 may be due to a high proportion of colorectal cancer patients having the Lewisa.lb phenotype, who cannot
synthesise these markers.
Cancer is the second cause of death in the USA and Europe,
and colorectal carcinoma is the second most prevalent malig-
nancy in these continents. The availability of a tumour
marker detectable in serum would be- helpful in confirming
the diagnosis of colorectal carcinoma. Since its discovery
(Gold & Freedman, 1965), the use of carcinoembryonic
antigen (CEA) as a tumour marker has become widespread.
Unfortunately, CEA appeared to be neither organ-specific,
nor tumour-specific (Bates & Longo, 1987). Therefore, CEA
is not very useful in the primary diagnosis of colorectal
carcinoma, but it has proved to be an effective monitor for
the follow-up of these cancers (Fletcher, 1986).
The search for new serum tumour markers has favoured
the development of monoclonal antibodies, which can be
raised and directed against circulating tumour-associated
antigens (TAA). The carbohydrate antigen 19-9 (CA 19-9)
has been described as potentially useful in the diagnosis of
colorectal carcinoma (Koprowski et al., 1979; Herlyn et al.,
1982). One year later, the carbohydrate antigen 50 (CA 50)
was recognised (Lindholm et al., 1983) as a promising diag-
nostic marker for cancers of colon and rectum. The monoc-
lonal antibodies (MAbs) used in the test kits of CA19-9 have
been shown to react with sialylated Lacto N-fucopentose II
(sialyl-Lea), a circulating epitope of the Lewis blood group
antigen (Magnani et al., 1982). The MAbs reactive with the
TAA CA 50 react with two different carbohydrate structures,
sialyl-Lea and sialosyl-lactotetraose (Nilsson et al., 1985).
More recently, the TAA 195 (CA 195) was described (Bray et
al., 1987). The MAbs recognising CA 195 have been shown
to react with both Lea and sialyl-Lea epitopes (Fukuta et al.,
1987). In the case of CA 50 it was reported that it might be
tumour-specific (Holmgren et al., 1984), whereas CA 19-9
and CA 195 might be organ-specific (Bhargava et al., 1987;
Sundaram et al., 1987). In comparison with CA 19-9, CA 195
seems to be less often elevated in benign disease, i.e., it might
be more specific for malignancies than CA 19-9 (Bhargava et
al., 1989).
It has been reported that individuals with the Lewisa-b-
phenotype cannot synthesise CA 19-9, because they lack the
necessary fucosyltransferase enzyme (Koprowski et al., 1982;
Magnani et al., 1983). In these individuals, CA 19-9 cannot
be used for the detection of colorectal cancers. The same
applies to CA 50 and CA 195, the production of which also
depends on the enzyme fucosyltransferase. The lack of fuco-
syltransferase concerns approximately 10% of the general
population (Watkins, 1980). CA 50, however, reacts to an
epitope also containing sialosyl-lactotetraose, which can be
produced by all individuals, irrespective of their Lewis
phenotype. It might therefore be a better marker for cancers
of colon and rectum than CA 19-9 and CA 195.
The aim of the present study was to compare the value of
CEA, CA 19-9, CA 50 and CA 195 in the detection of
colorectal carcinoma. For this purpose preoperative levels of
the four serum tumour markers in colorectal cancer patients
were compared with marker levels in patients with benign
colorectal disorders. To complete the overview of the value
of the preoperative levels of the markers, we also investigated
their prognostic significance for recurrence of disease.
Patients and methods
Patients
Between January 1985 and June 1990 preoperative blood
samples were collected from 257 patients who were going to
have a curative or palliative operation for colorectal car-
cinoma or an operation for a benign colorectal disorder.
Follow-up information on recurrence of disease or death was
available until November 1991. All diagnoses were histo-
logically confirmed after surgery. For the patients with
colorectal carcinoma the stage of disease, location and
differentiation of the tumour were assessed. Tumours were
staged according to Dukes' classification with Astler-Coller
modification (Astler & Coller, 1954). The type of disease was
assessed for the patients with a benign colorectal disorder. Of
the 257 patients, 198 had a colorectal carcinoma. Stage of
disease is shown in Table I. Distant metastases are referred
to as stage 'Dukes' D'. Two patients had a carcinoma of the
prostate and the stomach, respectively, and were therefore
excluded from the analyses. The 57 patients with a benign
colorectal disorder showed various forms of pathology,
which are summarised in Table II.
Laboratory methods
The blood samples were taken by venapuncture prior to
cytoreductive surgery. After clotting, the sera were cent-
rifuged for 10min at 2000 g and the serum samples were
stored at - 35'C until analysis. The immunoassays used were
the immunoluminometric assay BeriLux CEA (Behringwerke
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Table I Median and maximum levels of CEA, CA 19-9, CA 50 and CA 195 for patients
(n = 198)1 with colorectal carcinomas, for various stages of disease, according to Dukes'
classification with Astler-Coller modification
Median serum Median serum Median serum Median serum
Dukes' Number of CEA, ngml-t CA 19-9, Uml-' CA 50, Umt' CA 195, Uml-'
stage patients (max) (max) (max) (max)
A 10 2.6 18 11 10
5% (6.9) (45) (30) (10)
B1 36 2.1 24 11 10
18% (27) (84) (75) (32)
B2 47 4.3 35 15 10
24% (160) (150) (58) (55)
C1 9 2.8 30 11 10
5% (200) (65) (210) (110)
C2 47 3 24 10 10
24% (4,100) (1,500) (410) (1,100)
'D') 47 30 73 36 29
24% (6,600) (45,000) (9,300) (28,000)
Unknown 2 4.6 20 6.9 10
1% (5.7) (22) (8.1) (5)
Total 198 3.4 30 14 5
100% (6,600) (45,000) (9,300) (28,000)
'Some of the individual parameters have missing data.
Table II Diagnoses and median and maximum levels ofCEA, CA 19-9, CA 50 and CA 195 for patients
with a benign colorectal disorder (n = 57)
Median serum Median serum Median serum Median serum
Number of CEA, ngml-' CA 19-9, Uml-' CA 50, Uml-' CA 195, Uml-'
Diagnosis patients (max) (max) (max) (max)
Polyps or polyposis 11 2.4 24 13 10
21% (18) (49) (25) (12)
Diverticular disease 12 0.7 6.5 4.4 10
21% (11) (340) (140) (58)
Crohn's disease 16 2.1 16 8.3 10
28% (5) (36) (51) (15)
Ulcerous colitis 5 1.5 11 5.9 10
7% (4.9) (39) (18) (10)
Othera 8 1.3 18 9.6 10
14% (5) (92) (46) (20)
Unknown 5 2.3 27 14 10
9% (4.3) (50) (17) (10)
Total 57 1.9 19 9.5 10
100% (18) (340) (140) (58)
'Otherdiseasescomprisefatnecrosis; lipoma; appendicularinfiltrate;endometrioticcolon; fibroticlumen
stricture; nonspecified inflammation; pancreatic pseudocyste; perianal fistula.
AG, Marburg, Germany), the Tandem-R CA 195 immuno-
radiometric assay (Hybritech Inc., Dan Diego, CA, USA),
the microparticle enzyme immunoassay IMx CA 19-9
(Abbott Laboratories, Abbott Park, IL, USA) and the Canag
Delfia CA 50 time-resolved fluoroimmunoassay (Wallac Oy,
Turku, Finland). The performance and characteristics of
these methods have been described previously (Van der
Schouw et al., submitted; Wobbes et al., 1992).
The precision of the assays was calculated for the means of
duplicate determinations of several different serum pools in
terms ofwithin-assay and between-assay coefficients of varia-
tion (CVW and CVb, respectively) as described by Rodbard
(1974). The CV,'s ranged from 2.0% (CA 50) to 5.1%
(CEA), whereas the CVb's ranged between 6.2% (CA 195)
and 11.7% (CA 50).
Statistical methods
The usefulness of the serum markers for the primary diag-
nosis of colorectal carcinoma was assessed by cumulative
frequency distributions and Receiver Operating Characteris-
tic (ROC) curves. The cumulative frequency distributions
display the cumulative percentage of colorectal cancer
patients as well as of patients with benign colorectal dis-
orders against the serum marker concentration. The resulting
figures allow the reading of sensitivity and specificity at any
requested cut-off level for test positivity. Furthermore, it
shows the extent of overlap of the marker distribution of
carcinoma patients with that of the patients with benign
disorders. ROC curves plot the sensitivity against one minus
specificity at various cut-off levels of the diagnostic test. A
non-discriminating test will have an ROC curve which coin-
cides with the diagonal. A perfect test will have an ROC
curve in the upper left corner of the diagram (Metz, 1978;
Swets, 1973; Weinstein & Feinberg, 1980). The area under
the curve (AUC), ranging from 0.5 for a non-discriminating
test to 1.0 for a perfect test, is a measure for the diagnostic
ability of a test (Hanley & McNeil, 1982).
The usefulness ofcombinations ofmarkers was assessed by
ROC curves as well. Combinations ofthe markers were made
by adding and multiplying, respectively, the concentrations of
markers for individual patients.
The prognostic value of the markers with respect to first
recurrence of disease was assessed by fitting a Cox' propor-
tional hazards model for each marker, with time from
surgery to first recurrence of disease in months as the depen-
dent variable (Cox, 1972). Tumour-free status at the end of
the study and death were considered censored.
Results
Table I shows the median and maximum serum concentra-
tions of the four individual tumour markers for carcinoma
patients for the different stages of disease. Means are not
presented, due to the skew distributions of the four markers.150 Y.T. VAN DER SCHOUW et al.
To improve the clarity of the Tables, minimum levels of
marker concentration are not displayed either. These minima
approximate the lowest detectable concentration for all
disease stages, locations and grades of differentiation and no
increasing trend could be observed in the minima. Maximum
concentrations of CEA, CA 19-9 CA 50 and CA 195
increase with increasing extent of Eisease. In the case of
median levels this trend cannot be observed; they are approx-
imately similar in all stages of disease, except for 'Dukes' D'
(Table I). The various tumour locations comprised coecum,
ascending coecum, hepatic flexure, transverse colon, lienalic
flexure, descending colon, sigmoid, recto-sigmoid and rectum.
The tumour location does not show any relationship with the
marker concentrations. None of the markers show clear rela-
tions with the grade of differentiation of the tumours. It is
observed that the highest level of the marker occurs in
tumours of which the grade of differentiation is unknown,
but this can probably be explained by the stage of disease of
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these tumours, which were all 'Dukes' D'. Apparently, in
clinical practice the grade of differentiation is frequently not
established in patients with distant metastases. Table II pre-
sents median and maximum observed concentrations of the
markers in patients with benign colorectal disorders. It is
noted that the maximum concentration for all markers is
found in patients with diverticular disease.
Figures 1 through 4 display the cumulative frequency
distributions for the markers. They present a rather similar
picture; the distribution of the carcinoma patients shows an
80-90% overlap with that of the benign colorectal disorder
patients, but for all markers a cut-off point can be deter-
mined above which patients almost certainly have carcin-
omas. This point is indicated in each figure and varies from
18 ng ml-' for CEA to 340 arbitrary U ml-', 140 arbitrary
U ml-' and 58arbitraryUml' for CA 19-9, CA 50, and
CA 195, respectively.
Figure 5 presents the ROC curves and the corresponding
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Figure 1 Cumulative frequency distribution of colorectal cancer patients (198) and patients with a benign colorectal disorder (57)
for CEA.
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Figure 2 Cumulative frequency distribution of colorectal cancer patients (198) and patients with a benign colorectal disorder (57)
for CA 19-9.
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Figure 3 Cumulative frequency distribution of colorectal cancer patients (198) and patients with a benign colorectal disorder (57)
for CA 50.
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Figure 4 Cumulative frequency distribution of colorectal cancer patients (198) and patients with a benign colorectal disorder (57)
for CA 195.
AUC's for the four tumour markers. The ROC curves of the
newer markers all have an AUC of 0.65, with a 95% confi-
dence interval (95% Cl) of 0.58-0.73, which is rather low
and, moreover, even lower than that of CEA (AUC 0.70,
95% Cl 0.63-0.77), although the difference is very small and
not statistically significant. Various combinations of the
serum tumour markers did not result in a better discri-
minative ability (Figure 6).
Figure 7 shows tumour-free survival functions for two
categories of CA 50 (CA 50 < 13 Uml-I/CA 50 > 13 U
ml-'), adjusted for stage of disease (two categories; Dukes'
A, B1, B2/Dukes' C1, C2, 'D'). Due to the low number of
recurrences (16), division into more categories led to empty
cells. The other markers showed very similar pictures and are
therefore not shown. In a Cox' proportional hazards model
marker concentration was held continuous to investigate
whether a monotonous relationship with the risk of recur-
rence exists, but this could not be found at all, adjustment
for age (continuous) and stage of disease (two categories;
Dukes' A, Bi, B2/Dukes' Cl, C2, 'D') did not reveal any
association either (P = 0.5-0.9).
Discussion
Although earlier investigations indicated very promising
results for the serum tumour markers CA 19-9, CA 50 and
CA 195, these markers showed disappointingly low diagnos-
tic power in the present study. The very low median concen-
trations alone, presented in Tables I and II, point to the poor
discriminative ability of all markers tested. The ROC curves
are in accordance with this finding. The three newer markers
all have an almost identical ROC curve with an AUC of 0.65
(95% Cl 0.58-0.73). The ROC curve of CEA was even
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slightly better, having an AUC of 0.70 (95% Cl 0.63-0.77),
which, however, is not statistically significant. Organ-
specificity was not investigated in the present study, but the
tumour-specificity is disappointing. Even CA 50, which has
been reported to be tumour-specific (Holmgren et al., 1984)
does not show a better discriminative ability than CEA,
which is known to be increased in nonmalignant disorders
and healthy smokers (Moore et al., 1989). However, in the
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Figure 5 Receiver Operating Characteristic curves of CEA, CA
19-9, CA 50 and CA 195 for colorectal cancer patients (198) and
patients a with benign colorectal disorder (57). AUC = Area
under the curve; CEA: AUC = 0.70, 95% Cl 0.63-0.77; CA
19-9: AUC = 0.65, 95% Cl 0.58-0.73; CA 50: AUC = 0.65,
95% Cl 0.58-0.73; CA 195: AUC = 0.65, 95% Cl 0.58-0.73. At
an arbitrarily selected high specificity rate of 95% all markers
had low sensitivity rates, varying from 27% (CA 50), 28% (CA
19-9) and 34% (CA 195) to 39% CEA), indicating high numbers
of false negative test results at high levels of specificity.
100
90
80 /
70-
60
n 4 50
o40
C,)
0 10 20 30 40 50 60 70 80 90 100
100 minus Specificity (%)
Sum of markers Product of markers
Figure 6 Receiver Operating Characteristic curves for sum and
product of CEA, CA 19-9, CA 50 and CA 195 for colorectal
cancer patients (198) and patients with a benign colorectal
disorder (57). AUC = area under the curve; Sum: AUC = 0.71,
95% Cl 0.64-0.79; Product: AUC = 0.73, 95% Cl 0.66-0.80.
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Figure 7 Tumour-free survival ofcolorectal cancer patients (198)
in months according to CA 50-concentration and stage of disease.
Low CA 50: CA 50 < 13Uml-'; High CA 50: CA
50> 13 U ml-; Low stage: Dukes' A, BI or B2; High stage:
Dukes' C1, C2 or 'D'.
study of Holmgren et al. (1984), 58% of the carcinoma
patient group had disseminated metastases. Furthermore,
19% of the control group were patients with pneumonia and
68% were even healthy blood donors. The use of these
groups, with serum marker concentrations on both extreme
ends of the marker distribution, probably masked the fact
that patients with early stages of malignant disease have CA
50 concentrations comparable with those of patients with
benign colorectal disorders.
To investigate the similarity in the performance of the
markers further, Pearson correlation coefficients were cal-
culated for all markers as presented in Table III. CA 19-9,
CA 50 and CA 195 appeared to have a correlation of about
0.55-0.60 with CEA but, more interestingly, the new mark-
ers showed a very high mutual correlation with correlation
coefficients ranging from 0.91 to 0.99. Accordingly, it is not
surprising that they showed comparable diagnostic power for
colorectal carcinoma. Probably, these high correlations can
in part be explained by the reactivity of all three markers
with sialyl-Lea. However, some reports indicate enhanced, i.e.
more specific assay performance using MAbs that react with
both the Lea and the sialyl-Lea epitopes as is the case with
CA 195 (Fukuta et al., 1987). This is not confirmed by the
present study. CA 19-9 and CA 50 have been reported to
show identical diagnostic results (Roberts, 1988), although
CA 50 reacts with an epitope also containing sialosyl-lacto-
tetraose (Nilsson et al., 1985). These findings are in accor-
dance with our data.
Combinations of the four markers did not improve diag-
nostic performance significantly, as is clear from Figure 6.
This was to be expected from the high correlation between
the markers. Apparently, there is still discussion on the diag-
nostic value of combinations of markers. Some authors
report improved diagnostic power for a combination markers,
others report approximately equal diagnostic power (Kuusela
et al., 1984; Bray & Gaur, 1988; Bhargava et al., 1989).
Probably, the poor diagnostic power of all three new
markers can at least partly be explained by the lack of the
enzyme fucosyltransferase in approximately 10% of the
population (Watkins, 1980), who have a Lea4b phenotype and
Table III Pearson's correlation coefficients (P-value) for CEA,
CA 19-9, CA 50 and CA 195
CEA CA 19-9 CA 50 CA 195
CEA 1 0.57 0.59 0.59
(0.0001) (0.0001) (0.0001)
CA 19-9 1 0.93 0.91
(0.0001) (0.0001)
CA 50 1 0.99
(0.0001)
CA 195 1
80
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hence cannot synthesise CA 19-9, CA 50 and CA 195
(Koprowski et al., 1982; Magnani et al., 1983). Recently it
was suggested that the Leab phenotype is more frequent in
patients with urinary bladder (12.2%) and colorectal (23.8%)
carcinoma (Langkilde et al., 1991). However, in this study
the Lewis phenotypes were determined on the erythrocytes,
and it has been demonstrated that their phenotype can con-
vert from Lewis-positive to Lewis-negative (Hirano et al.,
1987). Therefore, as far as studies based on Lewis phenotype
determination are concerned, the hypothesis is yet to be
investigated in serum, which does not allow conversion
(Hirano et al., 1987) and on tumour tissue.
Only CEA has some relationship with the extent of the
disease, as can be concluded from the higher CEA concentra-
tions in patients with more extensive disease. Therefore,
unlike CEA, the markers CA 19-9, CA 50 and CA 195 are
probably neither useful for the primary diagnosis nor for the
staging of colorectal carcinoma. Although they were develop-
ed from colorectal cell lines (Koprowski et al., 1979;
Schwartz, 1990), there are indications that some of these
markers could play a role in the diagnosis of pancreatic
cancer (Staab et al., 1985; Paganuzzi et al., 1988; Bhargava et
al., 1988). In the case of CA 19-9 a sensitivity of 89% is
reported at a specificity level of 95% (Staab et al., 1985),
whereas a sensitivity of 81% at a specificity of 89% is
described for CA 50 (Paganuzzi et al., 1988) and a sensitivity
of 64% at a specificity of 94% for CA 195 (Bhargava et al.,
1988).
Our data show that none of the tumour markers had
prognostic value, that is, none of the markers could predict
recurrence of disease within 34 months after diagnosis
(median follow-up, maximum follow-up is 81 months).
The three new markers were evaluated in accordance with
a so-called first phase of diagnostic marker assessment as was
described recently (Van der Schouw et al., submitted). In that
paper it was indicated that the spectrum of participating
patients must represent the spectrum of patients that is seen
in clinical practice. The colorectal cancer patients as well as
the benign colorectal disease patients in the present paper are
a representation of the patients presenting to the out-patient
Department of General Surgery of a university hospital. The
promising diagnostic power of the serum tumour markers as
described in literature probably results from comparisons of
serum marker concentrations of colorectal cancer patients
with those of healthy individuals and patients with non-
colorectal benign disorders (Holmgren et al., 1984; Bhargava
et al., 1987).
The methods of statistical analysis used in this paper are
also put forward in those recently proposed guidelines (Van
der Schouw et al., submitted). They form a convenient way
of expressing the diagnostic power of a test, mainly because
they are independent of cut-off levels for test positivity. Such
an analysis shows sensitivities and specificities at all possible
cut-off points simultaneously. Cumulative frequency distribu-
tions show the relationship ofthese test characteristics for the
particular serum marker concentrations. Finally, ROC curves
provide one summary measure ofperformance, i.e. the AUC,
rather than two separate measures, i.e. sensitivity and
specificity, which have to be considered simultaneously. Fur-
thermore, ROC curves provide the possibility of comparing
multiple tests of which the results are expressed on different
scales, such as ngml-' or arbitrary U ml-' as is the case in
the present paper.
It can be concluded that CA 19-9, CA 50 and CA 195 do
not appear to be very useful in the primary diagnosis of
colorectal carcinoma. Probably, they are not of value in
staging the disease and in prognosis either. Investigation into
the value of the markers in the monitoring of colorectal
carcinoma and the diagnosis, staging and monitoring of pan-
creatic carcinoma is necessary and, indeed, in progress.
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